文献速递核素与放射性配体治疗肿瘤 PET/CT

以177Lu标记抗体靶向血管生成进行放射免疫治疗

Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-18

研究用177Lu标记抗CD105抗体TRC105,在4T1乳腺癌小鼠模型中评估生物分布、毒性及疗效。结果显示高剂量组肿瘤生长受抑、生存期显著延长,且未观察到脱靶毒性,作者认为该靶向药物可与其他治疗联用以延缓肿瘤生长。

要点

  • 177Lu-DTPA-TRC105在4T1肿瘤中1天与7天摄取分别为14.3±2.3%ID/g与11.6±6.1%ID/g(n=3)。
  • 高剂量组肿瘤生长显著抑制,生存期显著延长(p<0.001,所有组)。
  • 除非特异性IgG组外,多数组小鼠体重下降未超过10%,提示安全性。

核心结论

  • 177Lu-DTPA-TRC105在足够剂量下能够抑制肿瘤生长并带来显著生存获益,且无脱靶毒性。
  • 作者认为该靶向药物可与其他治疗方案联用以延缓肿瘤生长,使其他药物更有效。

研究设计与样本

  • 研究将抗CD105抗体TRC105与DTPA偶联后用177Lu标记(半衰期6.65天)。
  • Balb/c小鼠植入4T1乳腺癌细胞,设五个研究组:仅177Lu、仅TRC105、177Lu-DTPA-IgG(非特异性抗体)、低剂量177Lu-DTPA-TRC105和高剂量177Lu-DTPA-TRC105。
  • 通过体重测量和血液标志物分析监测毒性,注射后1天和7天进行生物分布研究。
  • 注射高剂量177Lu-DTPA-TRC105后1、7、30天对各组织进行离体组织学研究。

主要发现

  • 生物分布研究显示177Lu-DTPA-TRC105在4T1肿瘤中注射后1天与7天摄取分别为14.3±2.3%ID/g与11.6±6.1%ID/g(n=3),并从其他器官逐渐清除。
  • 高剂量组观察到显著肿瘤生长抑制,同时生存期显著延长(p<0.001,所有组)。
  • 多数研究组(除非特异性IgG组外)小鼠体重下降未超过10%,提示注射药物安全性。
  • 血清丙氨酸转氨酶水平几乎保持恒定,提示肝脏(该药物的主要清除器官)无损伤,离体组织学分析证实了这一点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Increased angiogenesis is a marker of aggressiveness in many cancers. Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic. CD105, or endoglin, has a primary role in angiogenesis in a number of cancers, making this a widely applicable target for targeted radioimmunotherapy. METHODS: The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with 177Lu (t 1/2 6.65 days). Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: 177Lu only, TRC105 only, 177Lu-DTPA-IgG (a nonspecific antibody), 177Lu-DTPA-TRC105 low-dose, and 177Lu-DTPA-TRC105 high-dose. Toxicity of the agent was monitored by body weight measurements and analysis of blood markers. Biodistribution studies of 177Lu-DTPA-TRC105 were also performed at 1 and 7 days after injection. Ex vivo histology studies of various tissues were conducted at 1, 7, and 30 days after injection of high-dose 177Lu-DTPA-TRC105. RESULTS: Biodistribution studies indicated steady uptake of 177Lu-DTPA-TRC105 in 4T1 tumors between 1 and 7 days after injection (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, respectively; n = 3) and gradual clearance from other organs. Significant inhibition of tumor growth was observed in the high-dose group, with a corresponding significant increase in survival (p < 0.001, all groups). In most study groups (all except the nonspecific IgG group), the body weights of the mice did not decrease by more than 10%, indicating the safety of the injected agents. Serum alanine transaminase levels remained nearly constant indicating no damage to the liver (a primary clearance organ of the agent), and this was confirmed by ex vivo histological analyses. CONCLUSION: 177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity. Thus, this targeted agent could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ehlerding EB, Lacognata S, Jiang D, et al. Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging. 2017. PMID: 28821931. doi:10.1007/s00259-017-3793-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。